A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders

BMC Psychiatry

Volumn 13, Issue , 2013, Pages

  Ghanizadeh, Ahmad ^a   Moghimi Sarani, Ebrahim ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Autism; Clinical trial; N acetylcysteine; Oxidative stress; Randomized; Therapy

Indexed keywords

ACETYLCYSTEINE; BIPERIDEN; CLONIDINE; FOLIC ACID; IMIPRAMINE; NORTRIPTYLINE; PLACEBO; RISPERIDONE; TOPIRAMATE; CYSTINE; N-MONOACETYLCYSTINE; NEUROLEPTIC AGENT;

ABDOMINAL PAIN; ABERRANT BEHAVIOR CHECKLIST; ADJUVANT THERAPY; ADOLESCENT; ARTICLE; AUTISM; BLURRED VISION; CHILD; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DSM-IV; FATIGUE; FEMALE; HUMAN; INCREASED APPETITE; IRRITABILITY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NERVOUSNESS; OUTCOME ASSESSMENT; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREMOR; ANALOGS AND DERIVATIVES; AUTISTIC DISORDER; DRUG COMBINATION; DRUG EFFECTS; TREATMENT OUTCOME;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; CHILD, PRESCHOOL; CYSTINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRRITABLE MOOD; MALE; RISPERIDONE; TREATMENT OUTCOME;

EID: 84880914412     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-13-196     Document Type: Article

References (47)

1. Kocovska E, Biskupsto R, Carina Gillberg I, Ellefsen A, Kampmann H, Stora T, Billstedt E, Gillberg C. The Rising Prevalence of Autism: A Prospective Longitudinal Study in the Faroe Islands. J Autism Dev Disord 2012, 42(9):1959-1966. 10.1007/s10803-012-1444-9, 22271195.
2. Ghanizadeh A. A preliminary study on screening prevalence of pervasive developmental disorder in schoolchildren in Iran. J Autism Dev Disord 2008, 38(4):759-763. 10.1007/s10803-007-0445-6, 17879153.
3. Samadi SA, Mahmoodizadeh A, McConkey R. A national study of the prevalence of autism among five-year-old children in Iran. Autism 2012, 16(1):5-14. 10.1177/1362361311407091, 21610190.
4. Elsabbagh M, Divan G, Koh YJ, Kim YS, Kauchali S, Marcin C, Montiel-Nava C, Patel V, Paula CS, Wang C, et al. Global prevalence of autism and other pervasive developmental disorders. Autism research: official journal of the International Society for Autism Research 2012, 5(3):160-179.
5. Pardo CA, Eberhart CG. The neurobiology of autism. Brain Pathol 2007, 17(4):434-447. 10.1111/j.1750-3639.2007.00102.x, 17919129.
6. State MW, Levitt P. The conundrums of understanding genetic risks for autism spectrum disorders. Nat Neurosci 2011, 14(12):1499-1506. 10.1038/nn.2924, 22037497.
7. Ghanizadeh A, Akhondzadeh S, Hormozi, Makarem A, Abotorabi M, Firoozabadi A. Glutathione-related Factors and Oxidative Stress in Autism, a Review. Curr Med Chem 2012, 19(23):4000-4005. 10.2174/092986712802002572, 22708999.
8. Leoncini S, De Felice C, Signorini C, Pecorelli A, Durand T, Valacchi G, Ciccoli L, Hayek J. Oxidative stress in Rett syndrome: natural history, genotype, and variants. Redox Rep 2011, 16(4):145-153. 10.1179/1351000211Y.0000000004, 21888765.
9. Melnyk S, Fuchs GJ, Schulz E, Lopez M, Kahler SG, Fussell JJ, Bellando J, Pavliv O, Rose S, Seidel L, et al. Metabolic imbalance associated with methylation dysregulation and oxidative damage in children with autism. J Autism Dev Disord 2012, 42(3):367-377. 10.1007/s10803-011-1260-7, 3342663, 21519954.
10. Ghanizadeh A. Oxidative stress may mediate association of stereotypy and immunity in autism, a novel explanation with clinical and research implications. J Neuroimmunol 2011, 232(1-2):194-195.
11. Parellada M, Moreno C, Mac-Dowell K, Leza JC, Giraldez M, Bailon C, Castro C, Miranda-Azpiazu P, Fraguas D, Arango C. Plasma antioxidant capacity is reduced in Asperger syndrome. J Psychiatr Res 2012, 46(3):394-401. 10.1016/j.jpsychires.2011.10.004, 22225920.
12. Essa MM, Guillemin GJ, Waly MI, Al-Sharbati MM, Al-Farsi YM, Hakkim FL, Ali A, Al-Shafaee MS. Increased markers of oxidative stress in autistic children of the sultanate of oman. Biol Trace Elem Res 2012, 147(1-3):25-27.
13. Ming X, Stein TP, Brimacombe M, Johnson WG, Lambert GH, Wagner GC. Increased excretion of a lipid peroxidation biomarker in autism. Prostaglandins Leukot Essent Fatty Acids 2005, 73(5):379-384. 10.1016/j.plefa.2005.06.002, 16081262.
14. Damodaran LP, Arumugam G. Urinary oxidative stress markers in children with autism. Redox Rep 2011, 16(5):216-222. 10.1179/1351000211Y.0000000012, 22005342.
15. Meguid NA, Dardir AA, Abdel-Raouf ER, Hashish A. Evaluation of oxidative stress in autism: defective antioxidant enzymes and increased lipid peroxidation. Biol Trace Elem Res 2011, 143(1):58-65. 10.1007/s12011-010-8840-9, 20845086.
16. Ghanizadeh A. Targeting Mitochondria by Olesoxime or Complement 1q Binding Protein as a Novel Management for Autism: A Hypothesis. Molecular Syndromology 2011, 2:50-52. 3343746, 22570645.
17. Ghanizadeh A, Berk M, Farrashbandi H, Alavi Shoushtari A, Villagonzalo KA. Targeting the mitochondrial electron transport chain in autism, a systematic review and synthesis of a novel therapeutic approach. Mitochondrion 2012, 2012.
18. Banji D, Banji OJ, Abbagoni S, Hayath MS, Kambam S, Chiluka VL. Amelioration of behavioral aberrations and oxidative markers by green tea extract in valproate induced autism in animals. Brain Res 2011, 1410:141-151.
19. Frustaci A, Neri M, Cesario A, Adams JB, Domenici E, Dalla Bernardina B, Bonassi S. Oxidative stress-related biomarkers in autism: Systematic review and meta-analyses. Free Radic Biol Med 2012, 52(10):2128-2141. 10.1016/j.freeradbiomed.2012.03.011, 22542447.
20. Chauhan A, Audhya T, Chauhan V. Brain Region-Specific Glutathione Redox Imbalance in Autism. Neurochem Res 2012, 37(8):1681-1689. 10.1007/s11064-012-0775-4, 22528835.
21. Al-Yafee YA, Al-Ayadhi LY, Haq SH, El-Ansary AK. Novel metabolic biomarkers related to sulfur-dependent detoxification pathways in autistic patients of Saudi Arabia. BMC Neurol 2011, 11:139. 10.1186/1471-2377-11-139, 3217885, 22051046.
22. Bowers K, Li Q, Bressler J, Avramopoulos D, Newschaffer C, Fallin MD. Glutathione pathway gene variation and risk of autism spectrum disorders. J Neurodev Disord 2011, 3(2):132-143. 10.1007/s11689-011-9077-4, 3188290, 21484198.
23. Vitvitsky V, Thomas M, Ghorpade A, Gendelman HE, Banerjee R. A functional transsulfuration pathway in the brain links to glutathione homeostasis. J Biol Chem 2006, 281(47):35785-35793. 10.1074/jbc.M602799200, 17005561.
24. Kern J, Geier D, Adams J, Garver C, Audhya T, Geier M. A clinical trial of glutathione supplementation in autism spectrum disorders. Med Sci Monit 2011, 17(12):682.
25. Ghanizadeh A. Could fever and neuroinflammation play a role in the neurobiology of autism? A subject worthy of more research. Int J Hyperthermia 2011, 27(7):737-738. 10.3109/02656736.2011.604665, 21967199.
26. Harrison C. Neurodevelopmental disorders: Glutamate blockers show benefit in models of autism spectrum disorders. Nat Rev Drug Discov 2012, 11(6):440-441.
27. Niederhofer H. Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism. J Clin Psychopharmacol 2007, 27(3):317-318. 10.1097/01.jcp.0000270082.30500.69, 17502791.
28. Ghanizadeh A. c-Kit+ cells transplantation as a new treatment for autism, a novel hypothesis with important research and clinical implication. J Autism Dev Disord 2011, 41(11):1591-1592. 10.1007/s10803-010-1174-9, 21225454.
29. Ghanizadeh A. Methionine sulfoximine may improve inflammation in autism, a novel hypothesized treatment for autism. Arch Med Res 2010, 41(8):651-652. 10.1016/j.arcmed.2010.10.012, 21199736.
30. Ghanizadeh A. Targeting of glycine site on NMDA receptor as a possible new strategy for autism treatment. Neurochem Res 2011, 36(5):922-923. 10.1007/s11064-010-0381-2, 21210221.
31. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011, 36(2):78-86. 3044191, 21118657.
32. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989, 6(6):593-597. 10.1016/0891-5849(89)90066-X, 2546864.
33. Schmaal L, Veltman DJ, Nederveen A, van den Brink W, Goudriaan AE. N-Acetylcysteine Normalizes Glutamate Levels in Cocaine-Dependent Patients: A Randomized Crossover Magnetic Resonance Spectroscopy Study. Neuropsychopharmacology 2012, 37(9):2143-2152. 10.1038/npp.2012.66, 3398721, 22549117.
34. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P. N-acetyl cysteine as a glutathione precursor for schizophreniaâ€" a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008, 64(5):361-368. 10.1016/j.biopsych.2008.03.004, 18436195.
35. Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, Kohlmann K, Jeavons S, Hewitt K. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial. J Affect Disord 2011, 135(1-3):389-394. 10.1016/j.jad.2011.06.005, 21719110.
36. Chan A, Paskavitz J, Remington R, Rasmussen S, Shea TB. Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension. Am J Alzheimers Dis Other Demen 2009, 23(6):571-585.
37. Ghanizadeh A, Derakhshan N, Berk M. N-acetylcysteine Versus Placebo for Treating Nail Biting, A Double Blind Randomized Placebo Controlled Clinical Trial. Anti-inflammatory & anti-allergy agents in medicinal chemistry 2013, 12(3):223-228. 10.2174/1871523011312030003, 23908665.
38. Kortsalioudaki C, Taylor RM, Cheeseman P, Bansal S, Mieli†Vergani G, Dhawan A. Safety and efficacy of N†acetylcysteine in children with non†acetaminophen†induced acute liver failure. Liver Transpl 2008, 14(1):25-30. 10.1002/lt.21246, 18161828.
39. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002, 347(5):314-321. 10.1056/NEJMoa013171, 12151468.
40. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, Carson WH, Findling RL. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009, 124(6):1533-1540. 10.1542/peds.2008-3782, 19948625.
41. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994, 24(5):659-685. 10.1007/BF02172145, 7814313.
42. Akhondzadeh S, Fallah J, Mohammadi MR, Imani R, Mohammadi M, Salehi B, Ghanizadeh A, Raznahan M, Mohebbi-Rasa S, Rezazadeh SA, et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34(1):32-36. 10.1016/j.pnpbp.2009.09.012, 19772883.
43. Ghanizadeh A, Sahraeizadeh A, Berk M. A Head-to-Head Comparison of Aripiprazole and Risperidone for Safety and Treating Autistic Disorders, a Randomized Double Blind Clinical Trial. Child Psychiatry Hum Dev 2013, [Epub ahead of print].
44. Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985, 89(5):485-491.
45. Shao J, Zhong B. Last observation carry-forward and last observation analysis. Stat Med 2003, 22(15):2429-2441. 10.1002/sim.1519, 12872300.
46. Ghanizadeh A, Derakhshan N. N-acetylcysteine for treatment of autism, a case report. J Res Med Sci 2012, 17(10):985-987. 3698662, 23826003.
47. Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA, Frazier TW, Tirouvanziam R. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry 2012, 71(11):956-961. 10.1016/j.biopsych.2012.01.014, 22342106.